Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same?

Basit Öğe Kaydı
dc.authoridYaman, Samet/0000-0003-4081-1070
dc.authoridkucuksahin, orhan/0000-0003-4530-2304
dc.authoridemmungil, hakan/0000-0001-5184-4404
dc.authoridIlgen, Ufuk/0000-0001-6443-6426
dc.authorwosidYaman, Samet/IRY-9714-2023
dc.authorwosidkucuksahin, orhan/GZA-3287-2022
dc.authorwosidilgen, ufuk/R-8761-2017
dc.authorwosidEmmungil, Hakan/J-9960-2019
dc.contributor.authorEmmungil, Hakan
dc.contributor.authorIlgen, Ufuk
dc.contributor.authorTuran, Sezin
dc.contributor.authorYaman, Samet
dc.contributor.authorKucuksahin, Orhan
dc.date.accessioned2024-06-12T10:58:03Z
dc.date.available2024-06-12T10:58:03Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThis study aimed to investigate the benefit of changing the pharmaceutical preparation of colchicine in Turkish Familial Mediterranean Fever (FMF) patients resistant to one preparation in terms of frequency of the attacks. Turkish adult FMF patients under treatment with an imported colchicine preparation-in the form of compressed tablet form-due to resistance to domestic colchicine preparations, which are film-or sugar-coated tablets, and not using anti-interleukin-1 or other biologic agents were included in the study. Baseline disease characteristics along with MEFV mutations were identified. Daily colchicine doses and attack frequencies before and after the pharmaceutical change were compared. Fifty patients resistant to coated tablet preparations of colchicine and under treatment with the compressed tablets were identified. The median duration of disease was 6 (interquartile range 2.7-14) years and duration under treatment with the imported colchicine was 21 (range 8-60) months. Eight (16%), ten (20%), and 32 (64%) patients had 0-3, 4-6, and more than 7 attacks per year, respectively, before the compressed tablets. After treatment with the compressed tablet form of colchicine, 44 (88%), 5 (10%), and 1 (2%) patients had 0-3, 4-6, and more than 7 attacks, respectively ( p < 0.0001). Daily colchicine doses were similar before and after the pharmaceutical change (1.85 +/- 0.47 vs 1.84 +/- 0.37 mg, p = 0.9). Turkish FMF patients with ongoing attacks under domestic coated tablet preparations of colchicine may benefit from the compressed colchicine tablets. This may be explained by the difference in pharmacokinetic properties of different colchicine preparations.en_US
dc.identifier.doi10.1007/s00296-019-04432-3
dc.identifier.endpage135en_US
dc.identifier.issn0172-8172
dc.identifier.issn1437-160X
dc.identifier.issue1en_US
dc.identifier.pmid31463607en_US
dc.identifier.scopus2-s2.0-85072010904en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage129en_US
dc.identifier.urihttps://doi.org/10.1007/s00296-019-04432-3
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19918
dc.identifier.volume40en_US
dc.identifier.wosWOS:000509304200017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofRheumatology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColchicineen_US
dc.subjectFamilial Mediterranean Feveren_US
dc.subjectPharmaceuticsen_US
dc.subjectPharmacokineticsen_US
dc.subjectResistanceen_US
dc.subjectPharmacokineticsen_US
dc.subjectFmfen_US
dc.subjectDiseasesen_US
dc.subjectBioavailabilityen_US
dc.subjectAmyloidosisen_US
dc.subjectDefinitionen_US
dc.subjectVolunteersen_US
dc.titleDifferent pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu